Evidence map›Paper›PMID 39447104›Full record

ArticleNeurology2024

Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.

Jack A Reeves, Alexander Bartnik, Dejan Jakimovski, Maryam Mohebbi, Niels Bergsland, Fahad Salman, Ferdinand Schweser, Gregory Wilding, Bianca Weinstock-Guttman, Michael G Dwyer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Hidden Pitfall in Multiple Sclerosis Imaging: How Standard Susceptibility-Weighted Imaging (SWI) May Miss Paramagnetic Rim Lesions.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  15. Review
  16. Review
  17. Multiple sclerosis: 2024 update.Free neuropathology · 2025
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jack A ReevesFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.ORCID 0009-0002-4079-5664
Alexander BartnikFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.
Dejan JakimovskiFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.ORCID 0000-0001-7114-4958
Maryam MohebbiFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.
Niels BergslandFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.ORCID 0000-0002-7792-0433
Fahad SalmanFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.
Ferdinand SchweserFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.ORCID 0000-0003-0399-9211
Gregory WildingFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.
Bianca Weinstock-GuttmanFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.ORCID 0000-0001-6732-151X
Michael G DwyerFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.
Robert ZivadinovFrom the Buffalo Neuroimaging Analysis Center (J.A.R., A.B., D.J., M.M., N.B., F. Salman, F. Schweser, M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Biostatistics (G.W.), School of Public Health and Health Professions, State University of New York at Buffalo; and Center for Biomedical Imaging at the Clinical Translational Science Institute (B.W.-G.), University at Buffalo, State University of New York.

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Deep Gray Matter Iron and Disease Progression in Multiple SclerosisR01NS114227 · NINDS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI SCHWESER, FERDINAND · 2021 to 2024
$1.5M
NCATS NIH HHS UL1 TR001412NINDS NIH HHS R01 NS114227
6 · The paper itself

Abstract

BACKGROUND AND

objectivesRecent technological advances have enabled visualizing in vivo a subset of chronic active brain lesions in persons with multiple sclerosis (pwMS), referred to as "paramagnetic rim lesions" (PRLs), with iron-sensitive MRI. PRLs predict future clinical disease progression, making them a promising clinical and translational imaging marker. However, it is unknown how disease progression is modified by PRL evolution (PRL disappearance, new PRL appearance). This is key to understanding MS pathophysiology and may help inform selection of sensitive endpoints for clinical trials targeting chronic active inflammation. To this end, we assessed the longitudinal associations between PRL disappearance and new PRL appearance and clinical disability progression and brain atrophy.

methodsPwMS and healthy controls (HCs) were included from a larger prospective, longitudinal cohort study at the University at Buffalo if they had available 3T MRI and clinical visits at baseline and follow-up timepoints. PwMS with sufficient clinical data for confirmed disability progression (CDP) analysis were included in a Disability Progression Cohort, and pwMS and HCs with brain volumetry data at baseline and follow-up were included in MS and HC Brain Atrophy cohorts. PRLs were assessed at baseline and follow-up and assigned as disappearing, newly appearing, or persisting at follow-up. Linear models were fit to compare annualized PRL disappearance rates or new PRL appearance (yes/no) with annualized rates of CDP and progression independent of relapse activity (PIRA) or with annualized rates of brain atrophy, adjusting for covariates including baseline PRL number and follow-up time. Statistical analyses were corrected for false discovery rate (FDR; i.e.,

resultsIn total, 160 pwMS (73.8% female; mean baseline age 46.6 ± 11.4 years; mean baseline disease duration 13.8 ± 10.6 years; median follow-up time 5.6 [interquartile range 5.2-7.8] years; 26.9% progressive MS) and 27 HCs (74.1% female; mean baseline age 43.9 ± 13.6 years; median follow-up time 5.4 [5.2-5.6] years) were enrolled. Greater PRL disappearance rates were associated with reduced rates of CDP (β mean = -0.262, 95% CI -0.475 to -0.049, DISCUSSION: Our results show that resolution of existing PRLs and lack of new PRLs are associated with improved clinical outcomes. These findings further motivate the need for novel therapies targeting microglia-mediated brain inflammation and adoption of clinical strategies to prevent appearance of new PRL.

Indexed as

AtrophyBrainDisease ProgressionMagnetic Resonance ImagingMultiple SclerosisAdultCohort StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedProspective Studies

Identifiers

PMID39447104
PMCPMC11509899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.